BioMarin Pharmaceuticals BMRN BRINEURA — Revenue
Discontinued — last reported Q4 '22
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by BioMarin Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The official record: BioMarin Pharmaceuticals’s 10-K, filed February 27, 2023, on SEC EDGAR. View the filing →
Ask your AI about BioMarin Pharmaceuticals's brineura — revenue.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is BioMarin Pharmaceuticals's BRINEURA — revenue?
- BioMarin Pharmaceuticals (BMRN) reported BRINEURA — revenue of $52.01M in Q4 2022.
- How has BioMarin Pharmaceuticals's BRINEURA — revenue changed year-over-year?
- BioMarin Pharmaceuticals's BRINEURA — revenue decreased by 59.3% year-over-year, from $127.89M to $52.01M.
- What does BRINEURA — revenue mean?
- The net revenue earned from the sales of a specific pharmaceutical product.
- How do you interpret BRINEURA — revenue?
- Rising revenue suggests strong clinical demand and effective commercial execution, whereas declining revenue may reflect pricing pressure or shifts in the competitive landscape.
- How does BRINEURA — revenue compare across companies?
- Similar to individual product revenue line items reported by peer biopharma firms in their segment disclosures.